Saffron (Crocus sativus) in the treatment of gastrointestinal cancers: Current findings and potential mechanisms of action

J Cell Biochem. 2019 Oct;120(10):16330-16339. doi: 10.1002/jcb.29126. Epub 2019 Jun 27.

Abstract

Gastrointestinal (GI) cancers are major causes of cancer-related mortality worldwide and include malignancies of the GI tract such as the stomach, liver, pancreas, small intestine, colon, and rectum. Promising and selective anticancer effects of pharmacologically active components of saffron (Crocus sativus L.) have been shown in preclinical in vitro and in vivo studies. Saffron and its active components including crocin, crocetin, and safranal exert their anticancer effects through different mechanisms, including induction of apoptosis, influence on the cell cycle, and regulation of host immune response and anti-inflammatory activities. This review summarizes the recent literature on the chemopreventive properties of saffron in GI cancers to have a better understanding of the potential underlying mechanisms and hence the appropriate management of these malignancies.

Keywords: crocetin; crocin; gastrointestinal cancers; saffron; safranal.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Cell Cycle / drug effects
  • Cell Differentiation / drug effects
  • Crocus*
  • Gastrointestinal Neoplasms / drug therapy*
  • Gastrointestinal Neoplasms / metabolism
  • Gastrointestinal Neoplasms / pathology
  • Humans

Substances

  • Anti-Inflammatory Agents
  • Antineoplastic Agents, Phytogenic